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Abstract Wasting/cachexia is prevalent among patients
with chronic kidney disease (CKD). It is to be distinguished
from malnutrition, which is defined as the consequence of
insufficient food intake or an improper diet. Malnutrition is
characterized by hunger, which is an adaptive response,
whereas anorexia is prevalent in patients with wasting/
cachexia. Energy expenditure decreases as a protective
mechanism in malnutrition whereas it remains inappropri-
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DOI 10.1007/s13539-011-0019-5ately high in cachexia/wasting. In malnutrition, fat mass is
preferentially lost and lean body mass and muscle mass is
preserved. In cachexia/wasting, muscle is wasted and fat is
relatively underutilized. Restoring adequate food intake or
altering the composition of the diet reverses malnutrition.
Nutrition supplementation does not totally reverse cachex-
ia/wasting. The diagnostic criteria of cachexia/protein–
energy wasting in CKD are considered. The association of
wasting surrogates, such as serum albumin and prealbumin,
with mortality is strong making them robust outcome
predictors. At the patient level, longevity has consistently
been observed in patients with CKD who have more muscle
and/or fat, who report better appetite and who eat more.
Although inadequate nutritional intake may contribute to
wasting or cachexia, recent evidence indicates that other
factors, including systemic inflammation, perturbations of
appetite-controlling hormones from reduced renal clear-
ance, aberrant neuropeptide signaling, insulin and insulin-
like growth factor resistance, and metabolic acidosis, may
be important in the pathogenesis of CKD-associated
wasting. A number of novel therapeutic approaches, such
as ghrelin agonists and melanocortin receptor antagonists
are currently at the experimental level and await confirma-
tion by randomized controlled clinical trials in patients with
CKD-associated cachexia/wasting syndrome.
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1 Introduction
Wasting is prevalent among patients with chronic kidney
disease (CKD). Eighteen to 75% of adults with end-stage
renal disease (ESRD) undergoing maintenance dialysis
showed some evidence of wasting [1, 2]. The differences
in prevalence of wasting may be due to the different ESRD
patient population mix reported, in the context of race, age,
and prevalence of comorbid conditions such as congestive
heart failure, diabetes mellitus, and liver disease. Wasting,
defined by the World Health Organization as low weight for
height [3], was thought to be the direct consequence of
inadequate nutrition intake or malnutrition. As a result, the
terms, “wasting”, “cachexia”, and “malnutrition” were used
interchangeably. Although inadequate nutrition may con-
tribute to wasting or cachexia, other factors including
systemic inflammation, perturbations of appetite-
controlling hormones from reduced renal clearance, aber-
rant neuropeptide signaling, insulin and insulin-like growth
factor resistance, and metabolic acidosis, may be important
in the pathogenesis of CKD-associated wasting [4–12]. The
wasting/cachexia syndrome in CKD patients consists of
anorexia, increased energy expenditure, decreased protein
stores characterized by a low serum albumin, and loss of
body weight and loss of muscle mass. Importantly, the
individual components of this syndrome all represent risk
factors for mortality in patients with CKD [13–16], which
is 100–200 times higher than the general population [17,
18]. The wasting/cachexia syndrome should be distin-
guished from malnutrition, which is defined as the
consequence of insufficient food or an improper diet.
Responses in malnutrition are adaptive whereas those in
wasting/cachexia are maladaptive. Hunger, which is an
adaptive response, characterizes malnutrition whereas an-
orexia is prevalent in patients with wasting/cachexia [13].
Energy expenditure decreases as a protective mechanism in
malnutrition whereas it remains inappropriately high in
cachexia/wasting [14]. In malnutrition, such as in simple
starvation, fat tissues are preferentially lost and lean body
mass (LBM) and muscle mass is preserved until the
advanced stages, whereas in cachexia/wasting, muscle is
wasted and fat is relatively underutilized [5, 10, 12].
Restoring adequate food intake or altering the composition of
the diet reverses malnutrition. Nutrition supplementation does
not totally reverse the cachexia/wasting syndrome [19, 20].
2 Diagnostic criteria of cachexia/protein–energy wasting
in CKD
Cachexia was recently defined as “a complex metabolic
syndrome associated with underlying illness and character-
ized by loss of muscle, with or without loss of fat” by a
group of scientists and clinicians participating in a
consensus conference on cachexia [21]. This group, which
later formed the Society for Cachexia and Wasting
Disorders (SCWD), and included participants with diverse
backgrounds encompassing many of the diseases states that
result in cachexia (such as cancer, HIV infection, conges-
tive heart failure (CHF), CKD, and chronic obstructive
pulmonary disease), identified weight loss and growth
failure as the most important clinical features of cachexia
in adults and children, respectively. In the context of CKD,
the term protein–energy wasting (PEW) has been proposed
by The International Society of Renal Nutrition and
Metabolism (ISRNM) to describe a “state of decreased
body stores of protein and energy fuels (body protein and
fat masses)” [22]. The ISRNM suggested that the term
cachexia be reserved for only the most severe forms of
PEW. However, there is no obvious distinction between
PEW and cachexia from a pathophysiology standpoint.
Limiting the term cachexia to the extreme forms of PEW
could be considered too restrictive. The term pre-cachexia
has been proposed to include the milder forms of wasting in
cancer patients [23].
The diagnostic criteria for cachexia (proposed by the
SCWD) and for PEW (proposed by the ISRNM) are
10 J Cachexia Sarcopenia Muscle (2011) 2:9–25similar, but not identical. Weight loss of at least 5% over
12 months or fewer, or a BMI<20 kg/m
2, is necessary for
the diagnosis of cachexia; three of the following five
additional criteria are also required: decreased muscle
strength, fatigue, anorexia, low fat-free muscle mass, and
abnormal biochemistry (including elevated inflammatory
markers such as C-reactive protein (CRP) or interleukin
(IL)-6, anemia [Hb<12 g/dL] and hypoalbuminemia;
Fig. 1). The proposed criteria for a diagnosis of PEW fall
into four distinct categories: (1) biochemical indicators, (2)
low body weight, reduced body fat or weight loss, (3)
decreased muscle mass, and (4) low protein or energy
intake (Table 1). In contrast to those for PEW, the
diagnostic criteria for cachexia emphasize lean mass
deficits and functional measures (such as muscle strength
and fatigue); in addition, anemia is considered a feature of
cachexia, but not of PEW.
Evidence of low body weight, reduced body fat or
weight loss are important indicators of cachexia/PEW.
Body mass index (BMI) is proposed as a method of
assessing appropriateness of body weight. Although BMI
gives little information about body composition, BMI is a
useful means of assessing PEW. BMI is strongly correlated
with LBM at the low end of the BMI spectrum [24], and
low BMI is a consistent predictor of mortality in both adults
[25, 26] and children [27] on maintenance dialysis.
However, BMI is not a very precise parameter of nutritional
status in patients in whom gross imbalances in fluid
homeostasis are commonly observed, such as in patients
with ESRD, CHF, and liver disease. Furthermore, in
patients with significant muscle wasting with relatively
well-preserved fat mass, small changes in BMI may well be
obscured by imbalances in fluid homeostasis. In this
respect, some investigators have preferred to use subjective
global assessment (SGA) as a surrogate marker in assessing
the nutritional status of patients with ESRD. Stenvinkel et
al. analyzed 268 patients with ESRD according to their
BMI and SGA. They found that 38% of their patients in the
low BMI group had a normal SGA, whereas 45% of the
patients in the normal BMI group and 17% in the high BMI
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Fig. 1 Conceptual representa-
tion of the definition: cachexia
results from adaptation to an
underlying illness such as cancer
or CKD. The illness creates an
environment that may be char-
acterized by inflammation, loss
of appetite (anorexia), low levels
of anabolic hormones, and ane-
mia. Decreased food intake and
anorexia result in loss of body
and muscle mass. In addition,
inflammation, insulin resistance,
and low levels of anabolic hor-
mones result in muscle wasting.
Reproduced with permission
from [21]
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showed that low BMI has no impact on cardiovascular
mortality whereas an SGA ≥2 was associated with a marked
increased in cardiovascular mortality by Kaplan–Meier
survival analysis [28]. Unintentional weight loss or reduc-
tion in weight of 5% or more over 3 months, or 10% or
more over 6 months are suggested as indicators of cachexia/
PEW, independent of absolute BMI [21]. Linear growth
failure in children with CKD was highlighted as central to
the diagnosis of cachexia [21], and has been associated with
a greater mortality risk in children on maintenance dialysis
[27]. However, the etiology of growth retardation in CKD
is multifactorial, including other factors such as delayed
sexual maturation, bone disease, acidosis, and growth
hormone/insulin growth factor resistance. Growth failure
may emerge as a necessary, but insufficient criterion, for
PEW in children with CKD.
Reduced muscle mass appears to be the most valid
criterion for the presence of PEW in CKD [22], and is also
emphasized in the diagnostic criteria for cachexia [21].
Mid-arm circumference has been shown to correlate with
quality of life and survival in adult patients on maintenance
hemodialysis (HD) [29]. Accurate assessment of the
adequacy of muscle mass is even more challenging. Dual
X-ray absorptiometry, near-infrared interactance, and bio-
electrical impedance have been used in investigations of
ESRD patients [30] but these techniques have limitations in
ESRD and are not currently accepted as clinically useful
tools. Indirect measures, such as creatinine appearance
(estimated by quantification of creatinine in a 24-h urine
collection and in the collected spent dialysate) have been
proposed as an index of muscle mass in patients with CKD
and ESRD [22]. Body fat mass lower than 10% of body
weight is considered an additional criterion for PEW in
adults with CKD [22] due to the known association
between total body fat below 10% and increased mortality
risk in adult maintenance dialysis patients [31]. A more
recent study showed that higher fat mass in dialysis patients
might actually be protective in survival predictability [32].
On the other hand, Cordeiro et al. [33] recently showed that
Table 1 Readily utilizable criteria for the clinical diagnosis of protein energy wasting in CKD
Criteria
Serum chemistry
Serum albumin <3.8 g 100 ml
−1 (Bromcresol Green)
a
Serum prealbumin (transthyretin) <30 mg 100 ml
−1 (for maintenance dialysis patients only; levels may vary according to GFR level for patients
with CKD stages 2–5)
a
Serum cholesterol<100 mg 100 ml
−1a
Body mass
BMI <23
b
Unintentional weight loss over time: 5% over 3 months or 10% over 6 months
Total body fat percentage <10%
Muscle mass
Muscle wasting: reduced muscle mass 5% over 3 months or 10% over 6 months
Reduced mid-arm muscle circumference area
c (reduction >10% in relation to 50th percentile of reference population)
Creatinine appearance
d
Dietary intake
Unintentional low DPI <0.80 gkg
−1 day
−1 for at least 2 months
e for dialysis patients or <0.6 gkg
−1 day
−1 for patients with CKD stages 2–5
Unintentional low DEI <25 kcal kg
−1 day
−1 for at least 2 months
e
At least three out of the four listed categories (and at least one test in each of the selected category) must be satisfied for the diagnosis of kidney
disease-related PEW. Optimally, each criterion should be documented on at least three occasions, preferably 2–4 weeks apart
Reproduced with permission from [22]
DEI dietary energy intake, DPI dietary protein intake, nPCR normalized protein catabolic rate, nPNA normalized protein nitrogen appearance
aNot valid if low concentrations are due to abnormally great urinary or gastrointestinal protein losses, liver disease, or cholesterol-lowering medicines
bA lower BMI might be desirable for certain Asian populations; weight must be edema-free mass, for example, post-dialysis dry weight. See text for the
discussion about the BMI of the healthy population
cMeasurement must be performed by a trained anthropometrist
dCreatinine appearance is influenced by both muscle mass and meat intake
eCan be assessed by dietary diaries and interviews, or for protein intake by calculation of normalized protein equivalent of total nitrogen appearance (nPNA
or nPCR) as determined by urea kinetic measurements
12 J Cachexia Sarcopenia Muscle (2011) 2:9–25abdominal fat deposition is linked to inflammation and
PEW, resulting in an increased mortality risk in mainte-
nance HD patients.
Anorexia is one of the suggested criteria for cachexia
[21], while low protein and/or energy intake is a criterion
for PEW [22]. Both subjectively reported anorexia [13, 34]
as well as measured low protein or energy intake has been
associated with increased mortality in adult ESRD patients
[35]. Anorexia is prevalent, in 30–40% in adult mainte-
nance HD patients, and is associated with higher concen-
trations of pro-inflammatory cytokines and higher levels of
erythropoietin hypo-responsiveness as well as poor clinical
outcome, including a fourfold increase in mortality, greater
hospitalization rates, and poor quality of life [13]. As male
ESRD patients seem to be more prone to inflammation-
associated anorexia than female patients, sex hormones
may play an important role in this context [34]. Anorexia is
prevalent in children with fairly mild CKD can be the
primary reason for growth failure [36]. Poor growth due to
inadequate intake has been observed in children with
glomerular filtration rate as high as 70 ml/min/1.73m
2
[37]. Growth of children with CKD is compromised when
energy intake fall below 80% of recommended daily
allowance [36].
Among biochemical indicators of PEW, low serum
albumin stands out as a consistent predictor of mortality
in epidemiological studies of both adult [38–42]a n d
pediatric [43] ESRD patients. A low serum albumin
concentration is by far the strongest predictor of mortality
and poor outcomes in adult ESRD patients on maintenance
dialysis when compared to any other risk factors [38, 39],
including traditional risk factors (hypertension, smoking,
hypercholesterolemia, diabetes, and obesity) and non-
conventional ones (anemia measures, oxidative stress,
minerals and bone surrogates, dialysis treatment and
technique) [44]. The sensitivity of serum albumin to predict
CKD patient outcomes is relatively high with such a
granularity of as little as 0.2 g/dL or even smaller [39,
40]. Dialysis patients with baseline serum albumin of even
0.2 g/dL higher or lower than other dialysis patients with
similar demographic and comorbidity constellations have
significantly lower or higher death risk, respectively. The
albumin–death association is highly incremental and linear,
and the mortality–predictability of serum albumin below
4.0 g/dL has virtually no cutoff level, below which the
association with death would cease or reverse [39, 40]. This
is in sharp contrast to most other outcome predictors in
CKD, which demonstrate U- or J-shape survival associa-
tions. Changes in serum albumin over time are associated
with proportional and reciprocal alterations in subsequent
death risk, in that a rise or drop in serum albumin by as
little as 0.1 g/dL over a few months period is associated
with improving or worsening survival, respectively [40].
Approximately two thirds of all maintenance dialysis
patients in the USA exhibit “relative hypoalbuminemia”,
i.e., a serum albumin <4.0 g/dL, as suggested by the
National Kidney Foundation Kidney Disease Quality
Outcome Initiative for the diagnosis of PEW [45]. In the
USA, and most other countries, serum albumin is measured
at least monthly to quarterly in all maintenance dialysis
patients, making it the most readily available PEW
biomarker. Dialysis clinics with superior patient care and
performance also exhibit higher serum albumin levels and
better survival rates, whereas those with inferior perfor-
mance have lower albumin levels [46, 47].
Relatively low serum prealbumin (e.g., <30 mg/dL) is
another indicator of PEW and a strong predictor of
outcomes in maintenance dialysis patients [48]. Two recent
studies showed that change in serum prealbumin over time
is associated with corresponding changes in survival of
ESRD patients [20, 48]. Even though baseline serum
prealbumin may not be superior to albumin in predicting
mortality in maintenance HD patients, prealbumin con-
centrations <20 mg/dL are associated with death risk
even in normoalbuminemic patients, and a fall in serum
prealbumin over 6 months is independently associated
with increased death risk [48]. An interesting observation
is that there is an inverse association between prealbumin
and percentage total fat. Dialysis patients with high serum
prealbumin have lower proportion of body fat as well as
higher proportion of muscle mass, which suggest that
normal serum prealbumin is associated with reversal of the
abnormal body composition in cachexia. Futhermore,
serum prealbumin strongly correlated with serum IL-6
independently in dialysis patients. Further analysis
showed that in dialysis patients with a baseline serum
prealbumin between 20 and 40 mg/dl, a drop of 10 mg/
dl was associated with 37% increase in death risk
independent of baseline markers of malnutrition inflam-
mation score (MIS), serum albumin, and inflammatory
markers [48].
Other nutritional indicators that predict survival in
maintenance dialysis patients include serum transferrin
level [49, 50] and nutritional scoring systems such as the
SGA [51] and MIS which also correlate with quality of life
[16]. Table 1 includes the list of potential PEW markers,
from a recent consensus paper about the definition of PEW
[2]. Low serum cholesterol has also been proposed as a
biochemical indicator of PEW. Circulating inflammatory
markers such as CRP, and proinflammatory cytokines such
as IL-6 may also be persistently elevated in PEW but were
not included as part of the criteria for diagnosis of PEW.
This is however evident that the concurrent presence of
PEW, inflammation, and CVD have additive interaction in
the association with mortality in patients with ESRD on
maintenance dialysis [52]
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in advanced CKD
The pathophysiology of cachexia/PEW syndrome is CKD
is multifactorial. An overview is summarized in Fig. 2 [22].
3.1 Anorexia
Anorexia is caused by a combination of factors including
altered taste [53], gastroesophageal reflux, delayed gastric
emptying, and elevated levels of numerous cytokines,
including IL-1, IL-6, and tumor necrosis factor (TNF)-α
[9]. Infants with high urine volumes may consume water in
volumes large enough to diminish their appetite for milk or
food. Furthermore, depression is common in ESRD patients
and may be important in the pathogenesis of anorexia and
PEW. Hung et al. [54] recently showed strong associations
between depression, inflammation, and serum albumin in
maintenance dialysis patients.
Furthermore, perturbations in appetite-regulating hor-
mones such as leptin [6] and ghrelin [55] may contribute to
anorexia in CKD (Fig. 3). As the kidney degrades leptin,
CKD is independently associated with a peripheral increase
in circulating leptin concentrations that are strongly and
inversely correlated with GFR in children [56]. Experimen-
tal uremic anorexia can be ameliorated by blockade of
leptin signaling through the hypothalamic melanocortin-4
receptor by the addition of agouti-related peptide (AgRP), a
melanocortin reverse agonist, suggesting a possible future
therapeutic strategy for PEW in CKD [4, 57]. Human data
on leptin and CKD–PEW are so far inconclusive. Hyper-
leptinemia has not been associated with worse appetite in
adult maintenance dialysis patients [58], and normalization
to body weight resulted in an obliteration of differences
between patients with different degrees of anorexia or
different caloric intake [59]. It has consequently been
suggested that because anorectic patients are subjected to
an increased body fat mass loss, leptin will primarily reflect
these fat stores thus obscuring any links to appetite [60].
Increased total ghrelin levels in CKD are primarily due
to the decreased degradation of ghrelin in the kidney [55,
61]. Whereas some studies found elevated ghrelin levels in
dialysis patients, levels were normal or even low in other
studies [62–64]. Multiple confounding factors may contrib-
ute to these seemingly contradicting findings. The two
major forms of circulating ghrelin are acylated (<10%) and
des-acyl ghrelin [61, 65, 66]. Acylated ghrelin promotes
food intake while des-acyl ghrelin induces negative energy
balance. Most of the investigators have used the traditional
radioimmunoassay method to analyze the sum of both
acylated and des-acyl ghrelin. However, only plasma des-
acyl ghrelin levels were elevated in CKD patients compared
with those patients with normal renal functions. Recent
studies have suggested that elevated des-acyl ghrelin le vels
could be involved in the anorexia on CKD patients [61].
Variations in residual renal function affect ghrelin metab-
olism. Nutritional status of CKD patients may also
influence the metabolism of ghrelin [61]. Assessment of
nutritional status has not been performed in most studies in
which chronic energy deficiency is evident in CKD
patients. In addition, nutrients may be introduced during
peritoneal dialysis in CKD patients. The absorption of
glucose may influence plasma ghrelin levels [67]. Longitu-
dinal studies, by following the same patients cohort in
terms of their serum ghrelin and nutritional status [68], and
by applying the discriminating ELISA assays to differen-
tiate acylated versus des-acyl ghrelin levels, are more likely
to reveal the pathophysiologic role of ghrelin in CKD [69].
3.2 Increased energy expenditure
Increased energy expenditure despite calorie insufficiency
is an important feature of cachexia often observed in CKD.
Wang et al. [14] reported elevated resting energy expendi-
ture (REE) in adult peritoneal dialysis (PD) patients and
that a higher REE was associated with increased mortality
in PD patients, which was partly explained by its close
correlations with residual kidney function, CVD, inflam-
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Fig. 2 Schematic representation
of the causes and manifestations
of the protein–energy wasting
syndrome in chronic kidney
disease. Reprinted with
permission from [22]
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al. [70] also reported that the treatment of infection and
subsequent resolution of elevated CRP is associated with
the normalization of elevated resting energy expenditure in
CKD patients, which is expected based on the known
hypermetabolic effects of inflammation. In addition to
inflammation, increased resting metabolic rate in CKD
may be due to increased activity of mitochondrial uncou-
pling proteins (UCPs). UCPs, a family of the mitochondrial
anion transporters, regulate ATP synthesis and the produc-
tion of reactive oxygen species. Uncoupling of mitochon-
drial electron transporter chain activity from the
phosphorylation of ADP results in thermogenesis [71].
UCP-1 and UCP-3 are key regulators of energy expenditure
in rodents [72] and humans [73]. Cheung et al. have shown
that UCP-1 mRNA and protein of brown adipose tissue was
increased in uremic mice. Brown adipose tissue UCP-3
protein content was higher in uremic mice than in pair-fed
control mice. This was associated with an elevation of basal
metabolic rate in uremic mice compared with controls [57].
3.3 Inflammation
There is evidence that inflammation is an important cause
of muscle wasting in CKD. Infusion of cytokines such as
TNF-α, IL-6, IL-1β, interferon (IFN)-γ enhanced muscle
protein degradation via the NFκβ pathway whereas
neutralization of these factors by genetic or pharmacolog-
ical approaches attenuates muscle wasting [9]. Raj et al.
[74] observed ineffective utilization of exogenous amino
acid for muscle protein synthesis in patients with ESRD.
These investigators hypothesized that increased expression
of IL-6 in the skeletal muscle augments muscle protein
catabolism and the amino acid released is used for acute
phase protein synthesis [75]. Inflammation activates the
ubiquitin-proteasome system, leading to cleavage of a
characteristic 14 kDa actin fragment in the soluble fragment
of muscle which is the hallmark of increased muscle
proteolysis in CKD [76]. Boivin et al. observed increased
caspase-3 activity in the skeletal muscle of ESRD patients
leading to increased generation of 14 kDa actin as well as
ubiquitinized carboxy-terminal actin fragment. They also
noted that the skeletal muscle of ESRD patients exhibited
augmented apoptosis [77]. Furthermore, this increased
muscle breakdown is not counterbalanced by a
corresponding increase of the anabolic pathways [78]
(Fig. 4).
NFκβ is a central integration site for pro-inflammatory
signals and a regulator of related target genes. TNF-α
enhances muscle wasting via NFκβ pathway [79]. NFκβ
activation is required for cytokine-induced loss of skeletal
muscle proteins [80] and is controlled by the Iκβ kinase
complex (IKK). Treatment with TNF-α, which induces
NFκβ activation, attenuates insulin-stimulated protein
synthesis [81]. TNF-α inhibits myocyte differentiation
through NFκβ activation, further enhancing muscle wast-
ing [82]. Activation of NFκβ signaling is sufficient to
induce significant muscle atrophy, as measured by increases
of amino acid excretion and tyrosine turnover in isolated
muscles via the upregulation of muscle Ring-finger protein-
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J Cachexia Sarcopenia Muscle (2011) 2:9–25 151. Thus, the IKKβ/NFκβ/MuRF1 signaling pathway is
important in the pathogensis muscle wasting associated
with pro-inflammatory cytokines such as TNF-α [83].
Furthermore, inflammation may affect muscle wasting
by multiple other mechanisms. Inflammation may suppress
insulin signaling and increases production of glucocorti-
coids [84]. Furthermore, myostatin signaling pathway is
recognized to functional counter to PI3k/Akt in mediating
muscle wasting. Myostatin regulates skeletal muscle mass
[85]. Myostatin-deficient mice display a marked increase in
muscle mass, due to muscle fiber hyperplasia and hyper-
trophy [86]. IGF-I is essential for development of skeletal
muscle and other tissues. IGF-I or the IGF-I receptor
knockout mice were significantly smaller than their control
littermates and had reduced muscle tissue, whereas over-
expressed IGF-I transgenic mice showed increased muscle
mass [87]. It has been proposed that the balance between
local expression of myostatin and IGF-I represents a yin-
and-yang system regulating muscle mass in CKD [88]. Sun
et al. [89] showed that uremia and exercise have opposing
effects in affecting this balance of myostatin and IGF-I in
the pathogenesis of uremic wasting. Signaling of myostatin,
IGF-I and SOCS-2 are important factors in the pathogenesis
of muscle wasting in CKD [78].
3.4 Insulin resistance
Resistance to actions of insulin on carbohydrate, protein,
and lipid metabolism has become an increasingly recog-
nized complication of CKD. An important consequence of
insulin resistance is its role in the pathogenesis of PEW in
CKD [90]. Pupim et al. [91] reported that maintenance
hemodialysis patients with diabetes mellitus have a higher
incidence of protein energy wasting as compared with CHD
patients who are not diabetic [91]. The same investigators
subsequently examined whether this unfavorable metabolic
state could lead to accelerated loss of lean body mass over a
period of 12 months [91, 92] and showed that chronic
dialysis patients with DM had significantly accelerated loss
of lean body mass compared to nondiabetic chronic dialysis
patients during the first year of maintenance HD. Multivar-
iate linear regression analysis revealed that the presence of
diabetes mellitus was the strongest predictor of lean body
loss independently of several clinically relevant variables
such as age, gender, serum albumin, presence of malnutri-
tion, presence of inflammation, baseline LBM, and renal
replacement therapy modality. Furthermore, even in the
absence of diabetes mellitus or severe obesity, insulin
resistance is detectable in maintenance dialysis patients and
is strongly associated with increased muscle protein
breakdown, primarily mediated by the ubiquitin–protea-
some pathway [93]. The underlying proteolytic mechanism,
elegantly demonstrated by Mitch et al. [76] in animal
models of insulin-deficiency and insulin resistance, appears
to involve a decrease in the activity of PI3K leading to
enhanced activation of the ubiquitin–proteasome pathway.
They also reported that a decrease in muscle PI3K activity
will activate Bax leading to stimulation of caspase-3
activity and increased protein degradation, which can be
reversed by administration of rosiglitazone, a peroxisome
proliferator-activated receptor (PPAR) agonist with pro-
found insulin-sensitizing capabilities [94]. Recent epidemi-
ological data indicate a survival advantage and better
nutritional status in insulin-free type II DM patients treated
with PPAR agonist thiazolidinediones [95].
3.5 Vitamin D deficiency
The complex metabolic abnormalities observed in CKD such
as vitamin D deficiency, obesity, metabolic acidosis, inflam-
mation, and accumulation of “uremic toxins” are believed to
contribute to the etiology of insulin resistance and acquired
defects in the insulin-receptor signaling pathway in this
patient population. Intriguing data have begun to emerge
linking the known vitamin D deficiency observed with CKD
and insulin resistance. A recent large cross-sectional analysis
of 14,679 subjects, also from NHANES III, revealed that
serum 25(OH)D3 levels and loss of renal function have an
independent and inverse relationship with insulin resistance
[96]. Active vitamin D compounds are distinguished by their
ability to bind with high affinity to vitamin D receptors not
only in the parathyroid glands, but in cells throughout the
body indicating a role for significant systemic effects. One
important nonclassical function of 1,25(OH)2D3 is as an
important modulator of insulin release from pancreatic islets
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Fig. 4 Pathophysiology of muscle wasting in CKD. Reprinted with
permission from [78]
16 J Cachexia Sarcopenia Muscle (2011) 2:9–25[97]. Intravenous vitamin D3 corrects glucose intolerance
and stimulates insulin secretion in response to a glucose
challenge in 1,25(OH)2D3 deficient animals [98]. Intrave-
nous 1,25(OH)2D3 administration corrected glucose intoler-
ance, insulin resistance, hypoinsulinemia as well as
hypertriglyceridemia in ESRD patients, in the absence of
parathyroid hormone suppression [99]. Metabolic acidosis is
a common complication of advanced CKD and may
represent yet another factor associated with increased insulin
resistance. Correction of metabolic acidosis with bicarbonate
supplementation has been demonstrated to improve insulin
resistance in animal models of uremia as well as in humans.
Oral bicarbonate replacement significantly improved insulin
resistance observed in ESRD patients with metabolic
acidosis. The mechanism may be mediated through upregu-
lation of 1,25(OH)2D3 levels potentially via enhanced renal
1-α hydroxylase activity [100].
4 Therapeutic strategies for prevention
and/or treatment of cachexia/PEW in CKD
4.1 Nutritional supplementation
Cheung et al. [4, 57] investigated impact of nutritional
supplementation on cachexia/wasting or malnutrition with a
mouse model of CKD by 5/6 nephrectomy. CKD mice was
fed ad libitum and compared with control sham-operated
pair-fed mice fed with CKD mice as well as sham-operated
mice fed ad libitum. CKD mice manifested anorexia; their
average food intake is 80% or less of control mice. CKD
mice gained significant less weight and lost both lean body
mass and fat mass compared to both control pair-fed mice as
well as control mice which are fed ad libitum. CKD mice
also had a higher basal metabolic rate and were energy
inefficient compared with both groups of control mice. CKD
mice fed ad libitum were also compared with CKD mice
forced-fed to bring their energy intake back to the level of
control mice fed ad libitum. Despite the increased energy
intake back to control levels, CKD mice still gained
significantly less weight and their lean body mass and fat
mass gains were significantly less than control values, which
might explain by the elevated metabolic rate and resultant
energy inefficiency. This experimental evidence clearly
shows that the nutritional status in CKD is more compatible
with cachexia/wasting than malnutrition and that nutritional
supplements may improve but will not fully correct the
wasting and elevated metabolic rate in CKD (Fig. 5).
There is evidence that nutritional therapy will improve
PEW in adult ESRD patients. Caglar et al. [101] studied 55
HD patients with PEW, who received conventional nutri-
tion counseling for 3 months, followed by 6 months of
thrice-weekly in-center intake of an 8-oz oral nutritional
supplement specifically designed for dialysis patients [102]
(Nepro™, Abbott Nutrition, Columbus, OH, USA), which
was provided during the dialysis treatment in the dialysis
clinics to ensure adherence. There were significant
increases in concentrations of serum albumin and prealbu-
min levels [101]. In another in-center, prospective and
controlled trial by Kalantar-Zadeh et al. [103]i n4 0H D
patients with hypoalbuminemia (≤3.8 g/dL), 20 HD patients
received the same 8-oz can of the dialysis patient-specific
oral supplement [96] accompanied by an additional 8-oz
can of a liquid anti-inflammatory and anti-oxidative oral
supplements that included borage oil and fish oil (Oxepa™,
Abbott Nutrition, Columbus, OH, USA). After 4 weeks of
thrice-weekly nutritional intervention during the HD treat-
ment, the pre-trial serum albumin level of 3.45±0.31 g/dl
increased to 3.68±0.34 g/dL (p=0.02) [103]. To the best of
our knowledge, there are 13 randomized controlled trials
[104–112] of nutritional therapy in ESRD patients. In eight
out of the nine randomized trials with serum albumin as a
surrogate outcome measure, significant improvement in
hypoalbuminemia was reported [104–112]. Serum albumin
did not increase significantly in the study by Fouque et al.
[113] but even in this study higher serum albumin and
prealbumin levels were observed in those who achieved
higher dietary protein intake. In the trial by Cano et al. [20],
186 malnourished HD patients were randomized to intra-
dialytic parenteral nutrition (IDPN) vs. no IDPN, while
both arms received oral supplements. Despite apparently
negative results for the IDPN, serum albumin and prealbu-
min levels increased in both groups under oral supplement
therapy, and greater survival was observed in those whose
serum prealbumin increased by more than 3 mg/dL after
3 months [20]. These data underline the importance of
serum prealbumin in the follow-up of patients during
nutritional support. Leon et al. [112] randomized 180 HD
patients to compare usual care with targeting specific
nutritional barriers, including poor nutritional knowledge,
poor appetite, help needed with shopping or cooking, low
fluid intake, inadequate dialysis dose, depression, difficulty
chewing, difficulty swallowing, gastrointestinal symptoms,
and acidosis. As part of the intervention, patients with poor
appetite or low fluid intake as nutritional barriers were
given limited amounts of oral nutritional supplements, such
as commercially available enteral nutrition drinks and
cookies. After 12 months, intervention patients had greater
increases in serum albumin levels, energy intake, and
protein intake compared to the control patients.
Poor growth due to inadequate intake has been observed
in infants with GFR as high as 70 ml/min/1.73m
2. Growth
of children with CKD is compromised when energy intake
fall below 80% of recommended daily allowance (RDA)
[36]. Increasing energy intake to 100% of the RDA can
increase weight gain and stabilize growth rates. However,
J Cachexia Sarcopenia Muscle (2011) 2:9–25 17there is no evidence that children will grow better if their
intake exceeds recommended amounts for healthy children.
Gastrostomy tube feeding leads to improvement in weight
and BMI-for-age z scores but not height-for-age z scores in
children with advanced CKD [37, 114, 115].
4.2 Exercise and physical activity
Several studies have been performed examining the effect
of exercise on nutritional status and functional status in
ESRD patients. Most of the studies have assessed the
effects of cardiopulmonary fitness training, whereas a few
have examined the role of resistance or strength training on
LBM in ESRD patients. Despite the proven efficiency of
resistance exercise as an anabolic intervention in the
otherwise healthy elderly population and certain chronic
disease states, recent studies in patients on maintenance
hemodialysis have not been encouraging in terms of long-
term improvements in markers of muscle mass. In the most
extensive study, Johansen et al. [116] studied whether
anabolic steroid administration and resistance exercise
training induce anabolic effects among patients who receive
maintenance hemodialysis. Exercise did not result in a
significant increase in LBM. Quadriceps muscle cross-
sectional area increased in patients who were assigned to
exercise and to nandrolone in an additive manner. On the
other hand, patients who exercised increased their strength
in a training-specific fashion, and exercise was associated
with an improvement in self-reported physical functioning.
Nandrolone deaconate and resistance exercise produced
anabolic effects among patients who were on hemodialysis.
Further studies are needed to determine whether these
interventions improve survival. Most recently, Cheema et
al. [117] studied whether 12 weeks of high-intensity,
progressive resistance training (PRT) administered during
routine hemodialysis treatment could improve skeletal
muscle quantity and quality versus usual care. While there
were no statistically significant improvements in LBM,
there were statistically significant improvements in muscle
attenuation, muscle strength, and mid-thigh and mid-arm
circumference in the PRT group relative to the nonexercis-
ing control group. Kopple et al. also studied resistance and
endurance exercise over a 6-month period in maintenance
dialysis patients and showed that while individuals assigned
to individual treatment groups did not show significant
improvement in their LBM, the overall group that exercised
showed a small but significant increase in total LBM by
dual-energy X-ray absorptiometry. These positive effects
were accompanied by upregulation in skeletal muscle of
mRNA and protein of insulin-like growth factor-I [118]. In
addition to exercise alone, preliminary studies indicated that
a combination of simultaneous exercise and nutritional
supplementation could augment the anabolic effects of
exercise, at least in the acute setting [119, 120]. However, a
recent randomized clinical trial failed to show further
benefits of additional resistance exercise training on long-
term somatic protein accretion above and beyond nutrition-
al alone [121]. These findings suggest that while that is
evidence that patients with ESRD can improve skeletal
muscle quality by exercise, longer training durations or
more sensitive analysis techniques are required before this
regimen can be recommended as therapy for cachexia/PEW
in CKD. Furthermore, there is no data on whether exercises
capacity tests can predict outcome in ESRD.
4.3 Appetite stimulant
Megestrol acetate is a synthetic derivative of progester-
one. Megestrol acetate may induce appetite via stimula-
tion of hypothalamic neuropeptide Y, modulation of
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Fig. 5 Impact of nutritional
supplementation on energy ho-
meostasis in experimental CKD.
N=5/6 nephrectomized, S sham-
operated controls, Supp mice
given nutritional supplements by
gavage. Modified from data
published in [4, 57]
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inhibition of inflammatory cytokines such as IL-1, IL-6,
and TNF. Administration of megestrol acetate to ESRD
patients resulted in improvements in appetite as well as
increasesinfatmass but decreases infat-freemass.Inthe only
double-blinded, crossover study [122], 24 maintenance
hemodialysis patients with anorexia were studied. Four
patients withdrew because of diarrhea and two died of
comorbid conditions. Of the 18 who completed the study, no
significant increase in albumin or LBM was observed. A
large number of side-effects were reported, including head-
aches, dizziness, confusion, diarrhea, hyperglycemia,
thrombo-embolism, uterine bleeding, peripheral edema,
hypertension, and adrenal insufficiency [123]. Thus, the
current experience in ESRD patients does not support the use
of megestrol acetate in clinical practice. Large randomized
control trials are needed to clarify the therapeutic role of
megestrol acetate in uremic anorexia.
4.4 Correction of acidosis
There is evidence that acidosis can induce muscle protein
catabolism and it could therefore be an important factor
contributing to loss of muscle protein in these conditions
[124]. Acidosis is associated with negative nitrogen balance
and degradation of branched-chain amino acids and protein
in patients with CKD. Stein et al. randomly assigned 200
PD patients with metabolic acidosis to treatment with a
dialysate solution of 35 mmol/l lactate or to a dialysate of
40 mmol/l lactate. After 1 year, both groups of patients had
a higher serum HCO3, had gained weight, and had an
increase in mid-arm muscle circumference compatible with
an increase in muscle mass [125]. Pickering et al.
determined if increasing the serum bicarbonate concentra-
tion of CAPD patients would improve their nutritional
status, increase plasma branched-chain amino acids
(BCAA) levels, and reduce ubiquitin mRNA in their
muscle as an index of suppressed activity of the ubiq-
uitin–proteasome system (UPS). Eight stable long-term PD
patients underwent vastus lateralis muscle biopsy before
being randomized to continue 35 mmol/l lactate dialysate or
convert to a 40 mmol/l lactate dialysate. After 4 weeks,
measurements were repeated. Increasing the serum bicar-
bonate level in CAPD patients leads to a downregulation of
proteolysis via the UPS pathway in muscle. There was also
an increase in plasma BCAA consistent with a decrease in
their degradation. The number of patients studied was
small, but the agreement between the results from both
human and animal studies provide compelling evidence that
muscle wasting in dialysis patients occurs via stimulation of
these catabolic pathways [126]. There are, however, few
treatments available for correcting metabolic acidosis apart
from alkali supplements such as NaHCO3 which, in CKD
patients, carry the risk of sodium loading and fluid
overload. Despite these theoretical risks, a recent study
using NaHCO3 supplementation in patients with CKD
actually led to a slower decline in their renal function as
well as improvement in their nutritional status. Following
correction of acidosis in these predialysis CKD patients,
dietary protein and calorie intake increased, accompanied
by improvements in serum albumin and LBM as assessed
by mid-arm muscle circumference [127].
4.5 Growth hormone
Acquired resistance to the anabolic actions of growth
hormone (GH) is a potential cause of the increased net protein
catabolism and wasting in patients with advanced CKD.
Several studies have shown that the administration of
recombinant human growth hormone (rhGH) at pharmaco-
logic doses induces a net anabolic action and improves food
utilization in uremic animal models. Similar findings were
reported in studies that used different methods to assess
protein homeostasis in patients with ESRD. Thus, pharmaco-
logic doses of rhGH constitute another potential anabolic
therapy in maintenance dialysis patients. Pupim et al. showed
that short-term GH therapy (for three consecutive days) led to
a 22% improvement in pre-HD whole-body protein homeo-
stasis. Essential amino acid muscle loss was also significantly
less during the pre-HD period when rhGH was administered.
The whole bodyanaboliceffects ofrhGHobservedduringthe
pre-HD period persisted throughout the entire study, as
evidenced by a lack of significant interaction or main effect
of treatment during HD and in the post-HD period [128].
Using stable isotope techniques to assess skeletal muscle
protein homeostasis, Garibotto et al. [129]s h o w e ds i g n i f i -
cant improvement in net muscle protein balance over a 6-
week administration of 50 μg rhGH in cachectic ESRD
patients on HD. Feldt-Rasmussen et al. [130]s h o w e dG H
treatment in ESRD patients increased lean body mass and
quality of life with no significant side-effects. Thus, rhGH
improves whole body protein homeostasis in chronic HD
patients in the short-term. A recent large multicenter
randomized controlled study designed to look at the effects
of daily rhGH administration on mortality was terminated
due to lack of recruitment [131]. Interestingly, the prelimi-
nary results of this trial indicated a beneficial effect on the
cardiovascular outcomes in maintenance hemodialysis
patients [Kopple et al., personal communication]. Thus,
more studies are needed to evaluate its long-term effect of
rhGH on outcomes in patients with advanced CKD.
4.6 Ghrelin agonists
The salutary effects of ghrelin on food intake and meal
appreciation suggest that it could be an effective treatment
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that a single subcutaneous injection of ghrelin enhances
short-term (3 days) food intake in PD patients, as evidenced
by a twofold increase in short-term energy intake. Subcu-
taneous ghrelin administration resulted in a twofold
increase in short-term energy intake in a cohort of nine
anorexic PD patients. Although these results are encourag-
ing, it is possible that the initial short-term increase in food
intake may be followed by subsequent decline, negating
any long-term beneficial effect of ghrelin administration.
Ashby et al. [133] evaluated the nutritional and cardiovas-
cular effect of daily subcutaneous ghrelin injection over a
period of 7 days in 12 anorexic PD patients. Their results
suggest that subcutaneous administration of synthetic
ghrelin stimulates food intake among dialysis patients over
the intermediate term. Energy expenditure, measured with
free-living pulse and motion monitors, is unchanged.
Importantly, there was no subsequent compensatory reduc-
t i o ni ne n e r g yi n t a k ei nt h e se patients; this suggests
potential long-term beneficial effects. No significant ad-
verse effects were observed during the study. Tolerance in
appetite-regulating centers and/or other factors may over-
ride the long-term appetite-stimulating effects of ghrelin.
Potential side effects of ghrelin therapy have to be
considered. Ghrelin infusion acutely induces lipolysis and
insulin resistance independently of GH and cortisol [124].
Thus, it will be important to follow subjects for the risk of
diabetes while on long-term ghrelin treatment. Finally, a
major limitation of treatment based on natural hormones is
the need for parenteral administration, because of the large
size of the molecule. The long-term therapeutic potential of
GHS-R agonists will likely rest with orally bioavailable
compounds. DeBoer et al. [134] recently showed that
ghrelin and small-molecule GHS-R agonist administration,
over a 2-week period, increased food intake and lean body
mass retention and decreased systemic inflammation and
muscle catabolism in rats with cachexia associated with
CKD. However, despite reports of the short- and
intermediate-term success of ghrelin administration in
treating anorexia and cachexia in ESRD patients, we must
await results of studies on its long-term efficacy in
improving appetite, weight gain, and lean body mass as
well as quality of life.
4.7 Leptin and melanocortin signaling modulation
Cheung et al. [4] demonstrated that uremia-associated
cachexia in mice could be ameliorated by genetic or
pharmacological blockade of leptin and central melanocortin
signaling via the MC4-R. The potential clinical utility of this
approach, however, is limited by the need to deliver AgRP
intracerebroventricularly. NBI-12i, a small molecule MC4-R
antagonist with high affinity, selectivity, and central nervous
system penetration after peripheral administration, has been
recently developed. Cheung et al. [57] examined the effects
of NBI-12i in a mouse model of uremic cachexia.
Intraperitoneal administration of NBI-12i effectively stimu-
lated food intake and weight gain in uremic mice.
Furthermore, NBI-12i exhibited additional desirable meta-
bolic effects beyond the nutritional effects of stimulating
appetite. NBI-12i-treated uremic mice gained LBM and fat
mass and had a lower basal metabolic rate, while vehicle-
treated and diet-supplemented uremic mice with the same
caloric intake lost both LBM and fat mass and had an
increased basal metabolic rate. The protective effects of NBI-
12i may be due to the normalization of the upregulation in
uncoupling protein expression seen in uremic mice. These
data underscore the importance of melanocortin signaling in
the pathogenesis of uremia-associated cachexia and demon-
strate the potential of peripheral administration of MC4-R
antagonists as a novel therapeutic approach. Recently, orally
active MC4-R antagonists have been introduced and hold the
promise of potential therapy for cachexia/PEW [135].
4.8 Ubiquitin–proteasome inhibitors
Cachexia/PEW in CKD is characterized by protein catabo-
lism. Protein synthesis is unchanged while protein degrada-
tion is increased in CKD. The daily rate of protein turnover in
cells is so high that even a small increase in protein
degradation will cause marked protein depletion over time.
The mechanism of increased protein degradation in CKD is
through the activation of the UPS. Complications of CKD,
including acidosis, insulin resistance, inflammation, and
increased glucocorticoid and angiotensin II production, all
activate the UPS to degrade muscle protein [136]. Recogni-
tion of the role of the UPS in the pathogenesis of cachexia/
wasting has led to the therapeutic use of bortezomib—a
proteasome inhibitor—in cancer patients. Inhibition of the
proteasome will block activation of NF-[kappa]B, which is a
common final pathway for signal transduction of many
cytokines, thought to be a central mechanism of cachexia/
wasting in many chronic disease states including CKD [137].
4.9 Dose and frequency of dialysis
Rocco et al. found no significant effect of HD dose or HD
membrane flux on longitudinal nutritional status in mainte-
nance HD patients as measured by appetite, serum albumin,
andanthropometricmeasures[138]. Galland et al. converted
eight patients from standard maintenance hemodialysis of
4–5 h three times a week to daily maintenance HD of 2–21/
2 h six times a week and observed significant improve-
ments in appetite and in nutritional status as reflected by
increases in serum albumin, serum prealbumin, cholesterol,
dry weight, and lean body mass after 6-month and 1-year
20 J Cachexia Sarcopenia Muscle (2011) 2:9–25intervals [139]. However, a recent randomized controlled
trial failed to confirm the beneficial effects of daily HD on
nutritional status in maintenance HD patients, as measured
by serum albumin [140].
5 Conclusion
Many questions remain about the description, classifica-
tion, and treatment of PEW or cachexia in children and
adults with CKD. Can a PEW scoring system effectively
predict morbidity and mortality? Can nutritional inter-
vention improve the biochemical and clinical disorders
related to PEW? If therapeutic interventions are effective
at improving indicators of PEW, will these interventions
improve clinical outcomes? New understanding of the
pathophysiology of PEW in CKD has the promise of
novel therapeutic strategies. Targeted anti-inflammatory
agents, already in clinical trials for autoimmune disor-
ders, including anti-TNF-α, anti-IL-1 and anti-IL-6 may
hold the potential of improving cachexia/PEW in CKD
patients. Other novel therapies such as ghrelin agonists,
melanocortin antagonists and ubiquitin–proteasome
inhibitors are also potentially exciting alternative strate-
gies. On the other hand, the basic question whether
nutritional supplementation can improve nutritional status
a n dh e n c em o r b i d i t ya n dm o r t a l i t yi nE S R Dp a t i e n t s
remains to be tested with appropriately designed ran-
domized controlled trials. Most of the information on the
novel strategies is currently at the experimental level and
awaits confirmation, again by randomized controlled
clinical trials in patients with CKD-associated cachexia/
PEW syndrome.
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